Abstract
In vivo enzyme levels are governed by the rates of de novo enzyme synthesis and degradation. A current lack of consensus on values of the in vivo turnover half-lives of human cytochrome P450 (CYP) enzymes places a significant limitation on the accurate prediction of changes in drug concentration-time profiles associated with interactions involving enzyme induction and mechanism (time)-based inhibition (MBI). In the case of MBI, the full extent of inhibition is also sensitive to values of enzyme turnover half-life. We review current understanding of CYP regulation, discuss the pros and cons of various in vitro and in vivo approaches used to estimate the turnover of specific CYPs and, by simulation, consider the impact of variability in estimates of CYP turnover on the prediction of enzyme induction and MBI in vivo. In the absence of consensus on values for the in vivo turnover half-lives of key CYPs, a sensitivity analysis of predictions of the pharmacokinetic effects of enzyme induction and MBI to these values should be an integral part of the modelling exercise, and the selective use of values should be avoided.
Keywords: Cytochrome P450, drug interactions, enzyme degradation, enzyme regulation, enzyme turnover, induction, mechanism-based inhibition
Current Drug Metabolism
Title: Cytochrome P450 Turnover: Regulation of Synthesis and Degradation, Methods for Determining Rates, and Implications for the Prediction of Drug Interactions
Volume: 9 Issue: 5
Author(s): Jiansong Yang, Mingxiang Liao, Magang Shou, Masoud Jamei, Karen Rowland Yeo, Geoffrey T. Tucker and Amin Rostami-Hodjegan
Affiliation:
Keywords: Cytochrome P450, drug interactions, enzyme degradation, enzyme regulation, enzyme turnover, induction, mechanism-based inhibition
Abstract: In vivo enzyme levels are governed by the rates of de novo enzyme synthesis and degradation. A current lack of consensus on values of the in vivo turnover half-lives of human cytochrome P450 (CYP) enzymes places a significant limitation on the accurate prediction of changes in drug concentration-time profiles associated with interactions involving enzyme induction and mechanism (time)-based inhibition (MBI). In the case of MBI, the full extent of inhibition is also sensitive to values of enzyme turnover half-life. We review current understanding of CYP regulation, discuss the pros and cons of various in vitro and in vivo approaches used to estimate the turnover of specific CYPs and, by simulation, consider the impact of variability in estimates of CYP turnover on the prediction of enzyme induction and MBI in vivo. In the absence of consensus on values for the in vivo turnover half-lives of key CYPs, a sensitivity analysis of predictions of the pharmacokinetic effects of enzyme induction and MBI to these values should be an integral part of the modelling exercise, and the selective use of values should be avoided.
Export Options
About this article
Cite this article as:
Yang Jiansong, Liao Mingxiang, Shou Magang, Jamei Masoud, Yeo Rowland Karen, Tucker T. Geoffrey and Rostami-Hodjegan Amin, Cytochrome P450 Turnover: Regulation of Synthesis and Degradation, Methods for Determining Rates, and Implications for the Prediction of Drug Interactions, Current Drug Metabolism 2008; 9 (5) . https://dx.doi.org/10.2174/138920008784746382
DOI https://dx.doi.org/10.2174/138920008784746382 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Macrovascular Complications of Type 2 Diabetes Mellitus
Current Vascular Pharmacology Heterocyclic Compounds: Effective α-Amylase and α-Glucosidase Inhibitors
Current Topics in Medicinal Chemistry PREFACE
Endocrine, Metabolic & Immune Disorders - Drug Targets Combined Chemotherapy or Biotherapy with Jasmonates: Targeting Energy Metabolism for Cancer Treatment
Current Pharmaceutical Biotechnology Vascular Protective Effects of Diabetes Medications that Mimic or Increase Glucagon-Like Peptide-1 Activity
Recent Patents on Cardiovascular Drug Discovery Probing Gallic Acid for Its Broad Spectrum Applications
Mini-Reviews in Medicinal Chemistry A Review of Natural and Synthetic Antioxidants Important for Health and Longevity
Current Medicinal Chemistry Vascular Disease and Insulin-Like Growth Factor-1
Vascular Disease Prevention (Discontinued) Opinion: [Withdrawal of Rimonabant – Walking the Tightrope of 21st Century Pharmaceutical Regulation?]
Current Drug Safety Advancement in Obesity Management: Leptin and Adiponectin Patents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Involvement of Hypoxia-Inducible Factors in the Dysregulation of Oxygen Homeostasis in Sepsis
Cardiovascular & Hematological Disorders-Drug Targets The Immune Protective Effect of the Mediterranean Diet against Chronic Low-grade Inflammatory Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Role of Oxidative Stress in Development of Cardiovascular Complications in Diabetes Mellitus
Current Vascular Pharmacology P2X Receptors and Diabetes
Current Medicinal Chemistry Gender Disparity in Lipid Target Achievements in High and Very High Atherosclerotic Cardiovascular Disease Risk Patients in the Arabian Gulf
Current Vascular Pharmacology Advances and Challenges in Drug Design of PPARδ Ligands
Current Drug Targets Metabolic Homeostasis and Colonic Health: the Critical Role of Short Chain Fatty Acids
Current Nutrition & Food Science Environmental (Lifestyle) Risk Factors for LADA
Current Diabetes Reviews Experience with Androgen Deprivation Therapy for Prostate Cancer in Japan and Future Perspectives
Current Cancer Drug Targets Oxidative Stress Signaling in Alzheimers Disease
Current Alzheimer Research